Cutaneous Lupus
Cutaneous Lupus - Related Videos
11:35
Dual-mode Imaging of Cutaneous Tissue Oxygenation and Vascular Function
0 Views •
Cited by 16 •
2010
A dual-mode imaging system was developed for non-contact assessment of cutaneous tissue oxygenation and vascular function.
06:44
Demonstration of Cutaneous Allodynia in Association with Chronic Pelvic Pain
0 Views •
Cited by 22 •
2009
A demonstration of the bedside test for cutaneous allodynia and its clinical implications.
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
0 Views •
Cited by 38 •
2015
The transfer of bm12 lymphocytes into a C57BL/6 recipient is an established model of systemic lupus erythematosus. Here we describe how to initiate disease using this model and how to characterize T follicular helper cells, germinal center B cells and plasma cells by flow cytometry.
11:36
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
0 Views •
Cited by 40 •
2012
Optimization of the experimental hamster model for cutaneous leishmaniasis by intradermal injection of Leishmania promastigotes at the dorsal skin. This approach is useful during inoculation, follow-up, characterization of lesions, application of treatments and obtaining of clinical samples. Locomotion, search for food and water, play and social activities are preserved.
08:20
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
0 Views •
Cited by 8 •
2020
This protocol describes the use of macromolecular crowding to create an in vitro human hypertrophic scar tissue model that resembles in vivo conditions. When cultivated in a crowded macromolecular environment, human skin fibroblasts exhibit phenotypes, biochemistry, physiology, and functional characteristics resembling scar tissue.
FAQs
Ultraviolet radiation, medications, and other triggers can promote autoantibody production and amplify immune signaling in susceptible individuals. These processes contribute to inflammation and injury of skin cells, helping explain why disease activity may follow environmental or medication-related exposures. Identifying relevant triggers can support clinical assessment and guide preventive counseling, particularly regarding sun protection.
Acute, subacute, and chronic patterns, including discoid lesions, can differ in appearance and clinical implications. Some presentations occur with involvement beyond the skin, whereas others remain primarily cutaneous. Recognizing the pattern helps clinicians distinguish related inflammatory or photosensitive conditions, assess the possibility of systemic disease, and address risks such as scarring or pigment changes.
Autoantibody production and immune signaling are central links between susceptibility or triggering exposures and visible skin disease. They promote inflammatory activity that injures skin cells, producing characteristic lesions. This mechanism provides the scientific basis for combining clinical examination with selected laboratory tests, rather than relying on lesion appearance alone when evaluating suspected cutaneous lupus.
Evaluation combines clinical examination, medical history, skin biopsy, and selected laboratory tests. The examination characterizes lesions and their distribution, while history can reveal relevant exposures, medications, or other clues. Biopsy and laboratory findings add complementary evidence, helping distinguish cutaneous lupus from other inflammatory or photosensitive conditions and supporting assessment for possible organ involvement.
A skin biopsy can provide tissue-based information when the appearance does not clearly separate cutaneous lupus from another inflammatory or photosensitive disorder. Selected laboratory tests contribute additional information about immune activity and possible disease beyond the skin. Used alongside history and examination, these tools improve diagnostic clarification and help determine appropriate follow-up.
Recognition supports timely treatment and consistent sun protection, while follow-up helps monitor for systemic lupus erythematosus. These priorities are important because ongoing disease may lead to scarring, pigment changes, or other complications. Management therefore extends beyond identifying lesions: clinicians also address preventable skin consequences and watch for evidence of broader disease involvement.